During a live event, Mar discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...

No revenue reported as development-stage programs advanced in key clinical trials. These 10 stocks could mint the next wave of millionaires › PDS Biotechnology (NASDAQ:PDSB), a clinical-stage ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Despite a strict clean eating regime, chronic stress and inactivity contributed to a young woman’s advanced colorectal cancer ...

Q1 2026 Management View James B. Frakes, CEO and CFO, stated the company advanced its lead oncology indication clinical program, delivered preclinical results supporting broader applications including ...

Discover PDS Biotechnology's Q2 2025 progress on groundbreaking cancer trials, including VERSATILE-003. Explore durable outcomes and market growth potential.

Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial ...